Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00547521
Registration number
NCT00547521
Ethics application status
Date submitted
19/10/2007
Date registered
22/10/2007
Date last updated
23/03/2015
Titles & IDs
Public title
Phase IIIB Subcutaneous Abatacept Monotherapy Study
Query!
Scientific title
A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate
Query!
Secondary ID [1]
0
0
IM101-173
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis (RA)
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - abatacept
Treatment: Drugs - Methotrexate (MTX)
Experimental: Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort - In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
Experimental: SC Abatacept Monotherapy Cohort - In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
Treatment: Drugs: abatacept
solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
Treatment: Drugs: Methotrexate (MTX)
Participants who were currently receiving methotrexate at a stable dose = 10 mg for at least 4 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study
Query!
Assessment method [1]
0
0
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Query!
Timepoint [1]
0
0
Day 113
Query!
Primary outcome [2]
0
0
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study
Query!
Assessment method [2]
0
0
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Query!
Timepoint [2]
0
0
Day 15, 29, 43, 57, 85,113 and 28, 56, and 85 days post last dose.
Query!
Primary outcome [3]
0
0
Number of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study
Query!
Assessment method [3]
0
0
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
Query!
Timepoint [3]
0
0
Day 15, 29, 43, 57, 85,113 and 28, 56 and 85 days post last dose.
Query!
Primary outcome [4]
0
0
Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for ELISA Results)
Query!
Assessment method [4]
0
0
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Query!
Timepoint [4]
0
0
Day 113.
Query!
Primary outcome [5]
0
0
Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for MSD Results)
Query!
Assessment method [5]
0
0
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
Query!
Timepoint [5]
0
0
Day 113.
Query!
Primary outcome [6]
0
0
Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for ELISA Results)
Query!
Assessment method [6]
0
0
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Query!
Timepoint [6]
0
0
Baseline and on day 15, 29, 43, 57, 85 and 113
Query!
Primary outcome [7]
0
0
Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for MSD Results)
Query!
Assessment method [7]
0
0
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum . It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL(MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
Query!
Timepoint [7]
0
0
Baseline and day 15, 29, 43, 57, 85 and 113.
Query!
Secondary outcome [1]
0
0
Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study
Query!
Assessment method [1]
0
0
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joint out of 28, the number of swollen joint out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96.
Query!
Timepoint [1]
0
0
Baseline and Month 4 (Day113).
Query!
Secondary outcome [2]
0
0
Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study
Query!
Assessment method [2]
0
0
A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline.
Query!
Timepoint [2]
0
0
Day 113.
Query!
Secondary outcome [3]
0
0
Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study
Query!
Assessment method [3]
0
0
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.
Query!
Timepoint [3]
0
0
Baseline and Month 4 (Day 113).
Query!
Secondary outcome [4]
0
0
Change From Baseline in All HAQ-DI Components at End of the 4-month Treatment Period (Day 113) of the ST Study
Query!
Assessment method [4]
0
0
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.
Query!
Timepoint [4]
0
0
Baseline and Month 4 (Day113).
Query!
Secondary outcome [5]
0
0
Cross Tabulations of Number of Participants With Positive and Negative Status for RF at Day 113 With Baseline, in the ST Study
Query!
Assessment method [5]
0
0
RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result). Cross-tabulation of frequency of seroconversion of RF at Day 113 with baseline, in the ST period, was provided.
Query!
Timepoint [5]
0
0
Baseline and Day 113.
Query!
Secondary outcome [6]
0
0
Number of Participants Who Died, Experienced SAEs, Experienced AEs or Who Discontinued Due to AEs During the ST Study
Query!
Assessment method [6]
0
0
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs or SAEs were recorded.
Query!
Timepoint [6]
0
0
Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Query!
Secondary outcome [7]
0
0
Number of Participants Who Experienced Drug-related SAEs and Drug-related AEs During the ST Study
Query!
Assessment method [7]
0
0
Drug-related AEs are those events with a relationship to the study therapy of certain; probable; possible; or missing. Drug-related SAEs are those events with any relationship to the study therapy.
Query!
Timepoint [7]
0
0
Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Query!
Secondary outcome [8]
0
0
Number of Participants With AEs of Special Interest During the ST Study
Query!
Assessment method [8]
0
0
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.
Query!
Timepoint [8]
0
0
Continuously through ST period (up to Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Query!
Secondary outcome [9]
0
0
Number of Participants With Marked Abnormalities (MAs) in Hematology During the ST Study: Hemoglobin, Hematocrit, Platelet Count, Erythrocytes and Leukocytes
Query!
Assessment method [9]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx.
Query!
Timepoint [9]
0
0
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Query!
Secondary outcome [10]
0
0
Number of Participants With MAs in Hematology During the ST Study: Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
Query!
Assessment method [10]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.
Query!
Timepoint [10]
0
0
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Query!
Secondary outcome [11]
0
0
Number of Participants With MAs in Serum Chemistry During the ST Study: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT) and Blood Urea Nitrogen (BUN)
Query!
Assessment method [11]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx.
Query!
Timepoint [11]
0
0
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Query!
Secondary outcome [12]
0
0
Number of Participants With MAs in Serum Chemistry During the ST Study: Creatinine, Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total) and Protein (Total)
Query!
Assessment method [12]
0
0
MAs= laboratory measurements marked as abnormal: creatinine: \>1.5 \* pre-Rx; sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN).
Query!
Timepoint [12]
0
0
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Query!
Secondary outcome [13]
0
0
Number of Participants With MAs in Serum Chemistry During the ST Study: Glucose (Fasting Serum), Albumin, Glucose (Serum), Phosphorous (Inorganic) and Uric Acid
Query!
Assessment method [13]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \< LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL.
Query!
Timepoint [13]
0
0
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Query!
Secondary outcome [14]
0
0
Number of Participants With MAs in Urinalysis During the ST Study: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC)
Query!
Assessment method [14]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).
Query!
Timepoint [14]
0
0
Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Query!
Secondary outcome [15]
0
0
Number of Participants With Anti-nuclear Antibody (ANA) Category at Day 113 of the ST Study
Query!
Assessment method [15]
0
0
ANA status was categorized as negative or positive corresponding to the following dilutions: less than 1:160 and greater than equal to 1:160.
Query!
Timepoint [15]
0
0
Day 113.
Query!
Secondary outcome [16]
0
0
Number of Participants With Anti-double Stranded DNA (dsDNA) Category at Day 113 of the ST Study
Query!
Assessment method [16]
0
0
Anti-dsDNA antibody status was categorized as negative or positive based upon assay-specific numeric cut-off values.
Query!
Timepoint [16]
0
0
Day 113.
Query!
Secondary outcome [17]
0
0
Number of Participants With Clinically Meaningful Vital Signs During the ST Study
Query!
Assessment method [17]
0
0
Vital signs measurements (including seated blood pressure, heart rate and temperature) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs/physical examination were clinically meaningful.
Query!
Timepoint [17]
0
0
At screening and on days 1,15,29,43, 57, 85 and 113.
Query!
Secondary outcome [18]
0
0
Minimum Plasma Concentration (Cmin) at Each Visit During the 4 Month Treatment Period of the ST Study
Query!
Assessment method [18]
0
0
Cmin serum abatacept concentration was obtained directly from the concentration-time data.
Query!
Timepoint [18]
0
0
Days 1, 15, 29, 43, 57, 85 and 113.
Query!
Secondary outcome [19]
0
0
Number of Participants With Abatacept Induced Antibody Responses Over Time During the LTE Study (ECL Method) - All Treated Participants in LTE Study
Query!
Assessment method [19]
0
0
The Meso-Scale Discovery (MSD) electrochemiluminescence (ECL) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10. Antibody responses included CTLA4 and possibly immune globulin (IG), IG and/or junction region.
Query!
Timepoint [19]
0
0
Days 197, 281, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, 1821, 1989, days post dose: 28, 56, 85, 168
Query!
Secondary outcome [20]
0
0
Change From Baseline in DAS28-CRP Score in the LTE Study - All Treated Participants in LTE Study
Query!
Assessment method [20]
0
0
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of 28, the number of swollen joints out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. Baseline was Day 1 of the ST Study; Day 113 was the end of the ST Study.
Query!
Timepoint [20]
0
0
Baseline, Day 113, Day 1345
Query!
Secondary outcome [21]
0
0
Number of Participants With Clinically Meaningful Improvement From Baseline in the LTE Study - All Treated Participants in LTE Study
Query!
Assessment method [21]
0
0
A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline. Baseline was Day 1 of the ST Study. Day 113 was the end of the ST Study.
Query!
Timepoint [21]
0
0
Baseline, Day 113, Day 1345
Query!
Secondary outcome [22]
0
0
Number of Participants in DAS28-CRP Remission and Number of Participants With Low Disease Activity (LDA) in the LTE Study - All Treated Participants in the LTE
Query!
Assessment method [22]
0
0
DAS28-CRP remission was defined as DAS28-CRP less than 2.6 and LDA was defined as DAS28-CRP less than, equal to 3.2. End of ST Study was Day 113.
Query!
Timepoint [22]
0
0
Day 113, Day 1345
Query!
Secondary outcome [23]
0
0
Change From Baseline in HAQ-DI in the LTE Study - All Treated Participants in LTE Study
Query!
Assessment method [23]
0
0
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered. Baseline was Day 1 in the ST Study and Day 113 was the last day of the ST Study.
Query!
Timepoint [23]
0
0
Baseline, Day 113, Day 1345
Query!
Secondary outcome [24]
0
0
Number of Participants With HAQ Responses in the LTE Study - All Treated Participants in the LTE STudy
Query!
Assessment method [24]
0
0
HAQ response was defined as an improvement of at least 0.3 units from baseline in the HAQ Disability Index (HAQ DI). Baseline was Day 1 of the ST Study and Day 113 was the last day of the ST Study.
Query!
Timepoint [24]
0
0
Baseline, Day 113, Day 1345
Query!
Secondary outcome [25]
0
0
Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study
Query!
Assessment method [25]
0
0
RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result).
Query!
Timepoint [25]
0
0
Continuously from start of LTE period up to 7 days post the last dose
Query!
Secondary outcome [26]
0
0
Change From Baseline in DAS28-CRP Score and Physical Function (HAQ-DI) Score in the LTE Study - Abatacept Monotherapy Subgroup
Query!
Assessment method [26]
0
0
Abatacept Monotherapy Subgroup consisted of participants who received SC abatacept and did not receive MTX in the ST and LTE Studies. DAS28-CRP: continuous variable which is a composite of 4 variables:number of tender joints out of 28, number of swollen joints out of 28, C-reactive protein (CRP) in mg/L and self assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. HAQ-DI includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score sums worst scores in each domain and divides by the number of domains answered. Baseline was Day 1 of Short Term Study. Day 113 was the last day of the Short Term Study.
Query!
Timepoint [26]
0
0
Baseline, Day 113, Day 1345
Query!
Secondary outcome [27]
0
0
Number of Participants in DAS 28-CRP Remission and Low Disease Activity (LDA) in the LTE Study - Abatacept Monotherapy Subgroup
Query!
Assessment method [27]
0
0
Remission was defined as DAS 28-CRP \< 2.6 and LDA was defined as DAS 28-CRP \<= 3.2. End of ST Study was Day 113. Abatacept Monotherapy Subgroup was defined as those participants who received as at least 1 dose of abatacept and did not receive MTX in the ST and LTE Studies.
Query!
Timepoint [27]
0
0
Day 113, Day 1345
Query!
Secondary outcome [28]
0
0
Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs), or Discontinued Due to AEs and/or SAEs During the LTE Period - All Treated Participants in LTE Study
Query!
Assessment method [28]
0
0
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs/SAEs are those events with a relationship to the study therapy of certain; probable; possible; or missing.
Query!
Timepoint [28]
0
0
Continuously from start of LTE Study up to 56 days post the last dose
Query!
Secondary outcome [29]
0
0
Number of Participants With AEs of Special Interest During the LTE Study - All Treated Participants in LTE Study
Query!
Assessment method [29]
0
0
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.
Query!
Timepoint [29]
0
0
Continuously from start of LTE Study up to 56 days post the last dose
Query!
Secondary outcome [30]
0
0
Number of Participants With Marked Abnormalities (MAs) in Hematology During the LTE Period - All Treated Participants in LTE Study
Query!
Assessment method [30]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.
Query!
Timepoint [30]
0
0
Continuously from start of LTE Study up to 56 days post the last dose
Query!
Secondary outcome [31]
0
0
Number of Participants With MAs in Serum Chemistry (Liver and Kidney Function) During the LTE Period - All Treated Participants in LTE Study
Query!
Assessment method [31]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT), Blood Urea Nitrogen (BUN) and Creatinine MA criteria: ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx; creatinine: \>1.5 \* pre-Rx.
Query!
Timepoint [31]
0
0
Continuously from start of LTE Study up to 56 days post the last dose
Query!
Secondary outcome [32]
0
0
Number of Participants With MAs in Serum Chemistry (Electrolytes, Glucose, Protein, and Metabolite) During the LTE Period - All Treated Participants in LTE Study
Query!
Assessment method [32]
0
0
Sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \<LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx).
Query!
Timepoint [32]
0
0
Continuously from start of LTE Study up to 56 days post the last dose
Query!
Secondary outcome [33]
0
0
Number of Participants With MAs in Urinalysis During the LTE Period: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) - All Treated Participants in LTE Study
Query!
Assessment method [33]
0
0
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).
Query!
Timepoint [33]
0
0
Continuously from start of LTE Study up to 56 days post the last dose
Query!
Eligibility
Key inclusion criteria
* Clinical diagnosis of Rheumatoid Arthritis
* Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog scale
* Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except for methotrexate
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Received treatment with rituximab
* Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
119
Query!
Recruitment in Australia
Recruitment state(s)
QLD,TAS,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - Maroochydore
Query!
Recruitment hospital [2]
0
0
Local Institution - Hobart
Query!
Recruitment hospital [3]
0
0
Local Institution - Malvern
Query!
Recruitment postcode(s) [1]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [2]
0
0
7001 - Hobart
Query!
Recruitment postcode(s) [3]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nebraska
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oklahoma
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
South Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Wisconsin
Query!
Country [13]
0
0
Mexico
Query!
State/province [13]
0
0
Distrito Federal
Query!
Country [14]
0
0
Mexico
Query!
State/province [14]
0
0
Jalisco
Query!
Country [15]
0
0
South Africa
Query!
State/province [15]
0
0
Kwa Zulu Natal
Query!
Country [16]
0
0
South Africa
Query!
State/province [16]
0
0
Western Cape
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
Query!
Trial website
https://clinicaltrials.gov/study/NCT00547521
Query!
Trial related presentations / publications
Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, Palmer W, Rodriguez C, Delaet I, Elegbe A, Corbo M. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013 May;65(5):718-28. doi: 10.1002/acr.21876.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00547521
Download to PDF